354 results about "Critically ill" patented technology

Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

A therapeutic mattress system and bed are disclosed for providing a comprehensive system of pulmonary and skin care therapies for the critically ill, immobilized patient. The features provided include rotational therapy, percussion therapy and pulsation therapy on a critical care bed frame with a low air loss patient support, all of which are controlled with various types of feedback from particularized sensors in the bed.

Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

New optical coherence tomography (OCT) techniques are disclosed which are designed to improve OCT glucose concentration measure accuracy and are capable of being performed on a continuous basis. New multi-wavelength optical coherence tomography (OCT) techniques are also disclosed and designed to reduce artifacts do to water. New optical coherence tomography (OCT) techniques are also disclosed for determining local profusion rates, local analyte transport rates and tissue analyte transport rates as a measure of tissue health, disease progression and state and tissue transplantation effectiveness.

A method of providing blood glucose therapy for a critically ill patient includes calculating a baseline nutrition feed requirement based on an algorithm that incorporates at least one of age, gender, and body size of the patient: determining a first blood glucose level; determining a second blood glucose level after a preselected time interval: determining a first body temperature reading: comparing the blood glucose levels: and administering either nutrition or insulin. The amount of nutrition administered to the patient is based on a first change in blood glucose level, the current body temperature reading, and a predetermined feed algorithm based on the second blood glucose level as well as the baseline nutritional feed requirement. The amount of insulin administered is based on a second change in blood glucose level, body temperature, and a predetermined insulin algorithm that incorporates at least one of the patient's body frame size, age, and gender.

The present invention is a system and method for inputting physician notes associated with the admission, diagnosis and treatment of patients in a healthcare system. It can be used for those who are critically ill as well as those who are engaged in more routine medical care. The present invention reduces the risk of medical treatment by populating specific patient information throughout the patient care system so that current physician notes are combined with other information and made available rapidly to hospital personnel at all levels of patient care. The present invention also assists in analyzing data in relation to risk associated with management choices and managing the patient care to reduce assessed risk.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

This invention relates to a novel method of reducing the mortality and morbidity in critically ill patients which comprises administering to the patients an effective amount of FGF-19.

The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype.

Measurement of blood pressure is one of the most common procedures done in a clinical and an ambulatory environment. It is usually done with a sphygmomanometer, where an inflatable cuff is attached to the arm of a patient and the systolic and diastolic pressures are determined, typically by listening to the Korotkoff sounds. Although this method is over 100 years old and widely used, it is well known that it has severe shortcomings.The present invention covers a novel device and method to continuously measure blood pressure using a noninvasive approach. A surface acoustic wave (SAW) pressure sensor is placed on a flexible substrate and placed on the wrist of a patient. This blood pressure sensing device communicates wirelessly with a monitor that is placed several meters away. The monitor can also be a wristwatch worn by the patient. The invention further encompasses a calibration procedure to convert the relative blood pressure values into absolute values.The main application for this novel device and method is in an intensive care environment where continuous monitoring of blood pressure on critically ill patients is important. Since the proposed method is inexpensive it can also be used by patients at home or even by healthy people (e.g. athletes). The reader system consists of an antenna and a standard computer (e.g. laptop) with signal processing software.

The invention discloses a spleen polypeptide extract extracted from the spleen tissue of mammals other than humans. The mammalian tissue is subjected to fat removal, homogenization, acid adjustment, freezing and thawing, pH adjustment, precipitation, heating, and centrifugation. Filtration, ultrafiltration and other steps to obtain the spleen polypeptide extract; the drug is an immunomodulatory drug that can improve and improve the immune function of the body, and can be used for primary and secondary cellular immune deficiency diseases (such as eczema, thrombocytopenia, multiple Infection syndrome, etc.), respiratory tract and lung infection, habitual cold, chronic hepatitis B, mumps, recurrent aphtha and other diseases, can be used in the treatment of leukopenia, leukemia, aplastic anemia caused by radiotherapy and chemotherapy , Lymphoma and other malignant tumors, to improve the malignant transformation of tumor patients, to improve postoperative or critically ill patients when they are weak.

Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood; and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the patient has elevated endotoxin levels. The methods can further comprise treating patients identified as having elevated levels of endotoxin with an endotoxin neutralizing therapy. The methods provide increased safety and a reduction in risk for critically ill patients.

The present invention relates to structured triglyceride, to parental nutrition emulsions comprising same, and use thereof. In particular, the invention relates to structured triglycerides comprising at least one medium chain C6-C12 fatty acid and at least one fatty acid selected from the group consisting of long chain C14-C18 or very long chain C20-C22 fatty acids, preferably each fatty acid is present in a predetermined position of the glycerol backbone. The parenteral nutrition emulsions are particularly useful for nourishing preterm-and term-infants, children, critically ill patients, and cancer patients.

The invention discloses a system for estimating the state of a critically ill patient in an obstetrical department, which comprises an input end, an output end and a data processing module. Firstly, measured heart rate, blood pressure, body temperature, breathing rate, pH, blood HCO-3 concentration, oxygen partial pressure, alveolar arterial blood oxygen tension difference, potassium ion concentration, hematokrit, white cell count, platelet count, fibrinogen, glutamic-oxaloacetic transaminase, albumin, bilirubin, creatinine, blood glucose concentration and nervous system grading data are input the system through the input end; the data processing module evaluates a death risk factor; and at last, the output end directly reflects the result of the patient and the expert suggestion. The invention can not only accurately evaluate the critical degree of the state of the patient and predict the death risk, but also can provide quantitative indexes for changing to a three-class hospital, and is beneficial to improve the treatment level of the critical state of the obstetrical department and lower the death rate of pregnant and lying-in women and perinatal infants.

The invention relates to a mobile internet intelligent wearable device. The device is used for achieving interaction response with external terminal equipment and comprises a central processing unit and a touch display screen, a wireless communication device, a data storage device, an internet speed monitoring device, an energy consumption monitoring device, a voiceprint recognition device, an audio input device, a rotatable camera, a camera vibration prevention processing device, an image encryption device, an environmental data collection device, a human body physiological data collection device, a physical health condition analyzer, a human body emotion recognizer, a three-axis acceleration sensor, a GPS locating device, a pressure sensor located on the touch display screen, a thermoelectric generator attached to the human skin, a projection device, an audio player and a vibrator which are connected with the central processing unit. The wearable device can actively and automatically recognize the emotion and physical health condition of a wearer, and the wearer can send out requesting information when the wearer is critically ill.

The present invention provides a method of determining the overall oxidative status of a body fluid or a tissue of a patient by measuring the oxidation-reduction potential (ORP) of the body fluid or tissue. The method has been found to be useful in the diagnosis, evaluation and monitoring of patients who have suffered a trauma (such as a head injury), patients suspected of being critically-ill or who are critically ill, patients who have an infection, and patients suspected of having a myocardial infarction (MI) or who have had an MI. The method has also been found useful in monitoring and evaluating exercise performance in patients. In addition, the method has been found useful in monitoring and evaluating stored blood products and patients who will receive such a product.

The invention provides an intacted protein enteral nutrition multi-polymerization agent, which comprises the following components in energy ratio: 12-15% of protein, 25-30% of fat, and 55-65% of carbohydrate. The intacted protein enteral nutrition multi-polymerization agent disclosed by the invention can sufficiently satisfy human-body needs and has the advantages of being complete in nutrition, balanced in mixture ratio and convenient to use; various components have complementary advantages and are promoted with each other; and the intacted protein enteral nutrition multi-polymerization agent has the positive effects of increasing the plasma protein level of patients and improving human-body nutrition condition, and is particularly suitable for providing nutrition support for patients during a perioperative period, critically ill patients, and other patients, and preventing and treating malnutrition.

A multi-functional medical facility permits emergent diagnostic imaging assessment, image guided therapeutic interventions, and open surgical procedures within the complex. The concept of bringing diagnostic and therapeutic imaging and operative equipment to the critically ill patient or the patient undergoing non-emergency, elective surgery, instead of bringing the patient to the equipment is a major clinical advantage that should improve efficiency, outcome and survival. An important economic advantage is that the components can be used separately and independently of each other, thus enabling them to also be used for routine emergency room (ER) work.

The present invention provides a method of determining the overall oxidative status of a body fluid or a tissue of a patient by measuring the oxidation-reduction potential (ORP) of the body fluid or tissue. The method has been found to be useful in the diagnosis, evaluation and monitoring of patients who have suffered a trauma (such as a head injury), patients suspected of being critically-ill, patients who have a viral infection, and patients suspected of having a myocardial infarction. The method has also been found useful in monitoring and evaluating exercise performance in patients. In addition, the method has been found useful in monitoring and evaluating stored blood products and patients who will receive such a product.

The invention discloses a medical tracheal catheter with safe and effective antibacterial performance. The organic silicon silver-loaded antibacterial coating tracheal intubation catheter is prepared by using tetraethoxysilane (TEOS) as a silicon source, gamma-methacryloxy propyl trimethoxyl silane (KH570) and methyl triethoxysilane (MTES) as organic-phase precursors and inorganic nano-silver as an antibacterial agent, adopting a sol-gel method, taking a tracheal intubation catheter as a base material and applying a surface antibacterial coating. The organic silicon silver-loaded antibacterial coating tracheal intubation catheter can be used for reducing related infectious complications in the tracheal catheter staying process, reducing the state of a patient, prolonging the catheter staying time to win precious time to successfully rescue of critically ill patients, and reducing economic burden of medical care, treatment risks and physical and psychological torture of patients, so that the disease prognosis of a tracheal intubated patient can be improved.

Method and apparatus are introduced for determining proportional cardiac output (CO), absolute left atrial pressure (LAP), and / or other important hemodynamic variables from a contour of a circulatory pressure waveform or related signal. Certain embodiments of the invention provided herein include the mathematical analysis of a pulmonary artery pressure (PAP) waveform or a right ventricular pressure (RVP) waveform in order to determine beat-to-beat or time-averaged proportional CO, proportional pulmonary vascular resistance (PVR), and / or LAP. The invention permits continuous and automatic monitoring of critical hemodynamic variables with a level of invasiveness suitable for routine clinical application. The invention may be utilized, for example, to continuously monitor critically ill patients with pulmonary artery catheters installed and chronically monitor heart failure patients instrumented with implanted devices for measuring RVP.

The invention provides anti-inflammatory and analgesic flurbiprofen axetil injection and a preparation method thereof. A mixture of 0.1-10 percent (w / v) of flurbiprofen axetil, 10-20 percent (w / v) of middle chain triglyceride (MCT) and 10-20 percent (w / v) of long chain triglyceride (LCT) is contained in the prescription (wherein the proportion of MCT and LCT is 4:1-1:4). The preparation method comprises the following steps: taking 1-5 percent (w / v) of lecithin as an emulsifying agent, taking 1-5 percent (w / v) of glycerol as an isotonic agent, finally adding disodium hydrogen phosphate, citric acid and water for injection and adjusting the pH value to 4-7 to prepare flurbiprofen axetil fat emulsion injection through colostrums, homogeneity and sterilization. The injection has the beneficial effects that the anti-inflammatory and analgesic effect is taken more quickly; the accumulation of fat of a human body can be reduced, and fatty tissues and liver load can be reduced; and the injection is more suitable for critically ill patients and people with poor liver functions and has lower toxic and side effects.

The invention discloses a mobile first-aid intensive care system for emergency and relates to the technical field of medical equipment. The mobile first-aid intensive care system comprises the compartment of an ambulance and a first-aid command center built in a hospital and is characterized in that a stretcher is arranged in an intensive care area in the compartment, and a control box and data relay equipment are mounted in an intensive care equipment storage cabinet in the intensive care area; when a medical worker presses one operation button on an operation box on the stretcher, the operation box generates a corresponding control instruction and transmits the control instruction to the control box, and the control box controls the working state of corresponding equipment according to the control instruction; meanwhile, medical staff on the ambulance can have a video call with the command staff of the first-aid command center and perform surgery under the instruction of the commandstaff, the whole system is high in intelligent level, the control operation of the medical staff is minimized, critically ill patients can be treated under the instruction of the hospital command staff, and prime time is fully utilized while the life safety of the patients is maximally guaranteed through the correct treatment manner.